Premium
A Potential Anti‐Pregnancy Vaccine Built by Conjugation of the β‐Subunit of Human Chorionic Gonadotropin to Adjuvant‐Active Muramyl Peptide
Author(s) -
SCHUTZE M.P.,
LECLERC C.,
JOLIVET M.,
DERIAUD E.,
AUDIBERT F.,
CHANG C.C.,
CHEDID L.
Publication year - 1987
Publication title -
american journal of reproductive immunology and microbiology
Language(s) - English
Resource type - Journals
eISSN - 1600-0897
pISSN - 8755-8920
DOI - 10.1111/j.1600-0897.1987.tb00125.x
Subject(s) - immunogen , toxoid , human chorionic gonadotropin , adjuvant , muramyl dipeptide , antibody , active immunization , immunization , chemistry , immunology , medicine , immune system , monoclonal antibody , hormone
The β‐subunit of human chorionic gonadotropin (hCG) conjugated to tetanus toxoid is being investigated as a vaccine for human fertility control. Initial clinical trials indicated that the level of antibody response induced by such an immunogen was not always sufficient to prevent pregnancy. Therefore, efforts are being made to evaluate new carriers for the β‐subunit and to select adjuvants to yield a more efficient vaccine. In the present report, we demonstrate that conjugates of the β‐subunit of hCG with muramyl di‐peptide (MDP), or its nonpyrogenic derivative murabutide, may have potential as an effective antipregnancy vaccine. The copolymer of βhCG and MDP administered with Al(OH) 3 to mice induced a high anti‐βhCG response, better than that induced by the conjugate of βhCG to tetanus toxoid given with Al(OH) 3 . Moreover, the antibodies induced by such an immunogen were competent for neutralizing the biological activity of hCG in vivo. Even more interesting, a copolymer of βhCG and of murabutide induced high levels of biologically active antibodies. This immunogen may represent a promising candidate for the development of an efficient vaccine for human fertility control.